Fredun Pharmaceuticals (539730) Q3 24/25 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter ended December 31, 2024, and ratified the incorporation of a wholly owned subsidiary, Fredun Retail Private Limited.

• Statutory auditors issued a limited review report with an unmodified conclusion on the quarterly results.

Financial highlights

• Total income for the quarter ended December 31, 2024, was ₹10,269.67 lakhs, up from ₹8,700.82 lakhs in the same quarter last year.

• Net profit for the quarter was ₹533.26 lakhs, compared to ₹422.31 lakhs in the same quarter last year.

• Earnings per share (EPS) for the quarter stood at ₹11.29, up from ₹8.99 year-over-year.

• For the nine months ended December 31, 2024, total income was ₹28,886.10 lakhs and net profit was ₹1,373.58 lakhs.

Outlook and guidance

• Expansion into the retail sector through the new wholly owned subsidiary aims to broaden the company’s retail chain.